This article summarized the latest R&D progress of procaine hydrochloride, the Mechanism of Action for procaine hydrochloride, and the drug target R&D trends for procaine hydrochloride.
AChE is responsible for breaking down the neurotransmitter acetylcholine, which is involved in various physiological processes such as muscle contraction, cognition, and memory.
This article summarized the latest R&D progress of proxalutamide, the Mechanism of Action for proxalutamide, and the drug target R&D trends for proxalutamide.
This article summarized the latest R&D progress of moxifloxacin hydrochloride, the Mechanism of Action for moxifloxacin hydrochloride, and the drug target R&D trends for moxifloxacin hydrochloride.
This article summarized the latest R&D progress of mupirocin calcium, the Mechanism of Action for mupirocin calcium, and the drug target R&D trends for mupirocin calcium.
Recently, AstraZeneca announced that the National Medical Products Administration (NMPA) of China has approved C5 complement inhibitor Eculizumab for the treatment of adults.
This article summarized the latest R&D progress of nicardipine hydrochloride, the Mechanism of Action for nicardipine hydrochloride, and the drug target R&D trends for nicardipine hydrochloride.
This article summarized the latest R&D progress of nitrendipine, the Mechanism of Action for nitrendipine, and the drug target R&D trends for nitrendipine.
Recently, UCB announced that the FDA has approved Bimzelx(bimekizumab) for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic treatment or phototherapy.